Moximed Inc, a developer of unicompartmental load absorber implants for active patients with painful knee osteoarthritis, has raised $50 million in Series C funding. The company’s investors include Advent Life Sciences, Future Fund, NEA, Morgenthaler Ventures, GBS Venture Partners and Vertex Healthcare. In conjunction with the funding, Dr. Shahzad Malik, a general partner at Advent Life Sciences and Brigitte Smith, a managing director at GBS Venture Partners, have been added to Moximed’s board of directors.
